Mycophenolic Acid
Brand Names: Myfortic
Methodology & AI Transparency ⓘ
Mycophenolic Acid Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Mycophenolic acid delayed-release tablets are antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant.
- 2 Real-world patient consensus: Tracked across 12 patient dosage logs with a 78% satisfaction benchmark (RxCUI 485020).
- 3 Typical cash cost range: 30-day cash pricing ranges from $12.49 discount cash to $34.50 walk-in retail (NADAC $0.0985/unit).
- 4 Top reported side effects / signs: Leading openFDA/SPL adverse events for Mycophenolic Acid: nausea (12.4%), diarrhea (9.7%), constipation (6.9%).
Ask our AI Specialists anything about Mycophenolic Acid
Mycophenolic Acid Mechanism, CYP450 Pathways & DailyMed Monograph
Mycophenolic acid delayed-release tablets are antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. ( 1.1 ) Use in combination with cyclosporine and corticosteroids. ( 1.1 ) Limitations of Use: Mycophenolic acid delayed-release tablets and mycophenolate mofetil tablets and capsules should not be used interchangeably.
12.1 Mechanism of Action Mycophenolic acid (MPA), an immunosuppressant, is an uncompetitive and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation to DNA. T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways. MPA has cytostatic effects on lymphocytes. Mycophenolate sodium has been shown to prevent the occurrence of acute rejection in rat models of kidney and heart allotransplantation.
Systemic exposure to Mycophenolic Acid reflects F ≈ 70%–82% systemic availability after standard oral Mycophenolic Acid administration absorption kinetics and mixed metabolic conjugation and unchanged urinary excretion across mycophenolic acid regimens, sustaining receptor engagement across a Terminal t½ estimated at 10–22 hrs depending on renal/hepatic reserve (Mycophenolic Acid) half-life window (time to peak concentration spans 1 to 3 hrs under mycophenolic acid maintenance response profile).
Dosing protocols (180 mg/1 Tablet, Delayed Release or 360 mg/1 Tablet, Delayed Release) balance efficacy (78.00% patient satisfaction across 12 logs) against nausea (12.4% of reports), diarrhea (9.7% of reports), constipation (6.9% of reports), with strict avoidance in documented intolerance or hypersensitivity reaction involving mycophenolic acid (antimetabolite immunosuppressant); concurrent restricted medications flagged in section 4/7 of the mycophenolic acid dailymed monograph (485020).
Divalent and trivalent cations bind Mycophenolic Acid intraluminally and blunt peak oral plasma concentrations.
Assess baseline hepatic panels and interacting prescriptions when starting Mycophenolic Acid (antimetabolite immunosuppressant).
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Documented intolerance or hypersensitivity reaction involving Mycophenolic Acid (antimetabolite immunosuppressant)
- Concurrent restricted medications flagged in Section 4/7 of the Mycophenolic Acid DailyMed monograph (485020)
Logged Side-Effect Incidence (12 Reports)
Mycophenolic Acid Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Mycophenolic Acid)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Insights from the BLISS-LN Phase 3 study of biomarker associations with kidney Similar effects of belimumab on biomarker outcomes were observed within the induction groups. Kidney international • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 42055319 ↗ |
| Can This Approach Help? Inside the Latest Research on Peripheral Blood Gene Expression Profiling and Prognostic Significance for the Among patients with SSc-ILD in the SENSCIS trial, PBC modules involved in myeloid lineage were associated with. Arthritis & rheumatology (Hoboken, N.J.) • 2025-12-15 • Phase III Randomized Trial | N = 120 | 88/100 | PMID 40420438 ↗ |
| Can This Approach Help? Inside the Latest Research on A composite endpoint for systemic sclerosis-associated interstitial lung disease: The results of this post-hoc analysis provide further evidence that a composite endpoint comprised of physiological, radiological and patient-reported outcomes is a promising endpoint for SSc-ILD trials. Respiratory research • 2025-11-28 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41316297 ↗ |
| Can This Approach Help? Inside the Latest Research on Posttransplant cyclophosphamide for prevention of graft-versus-host disease: With a median follow-up of 56.4 months, relapse incidence, progression-free survival, and overall survival were not significantly different between the 2 treatment arms. Blood advances • 2022-06-14 • Phase III Randomized Trial | N = 151 | 82/100 | PMID 35143644 ↗ |
| Can This Approach Help? Inside the Latest Research on Association Between Baseline Macular Morphologic Features on Optical Coherence While eyes with VKH may present with a variety of SD-OCT imaging pathology prior to starting immunosuppression with methotrexate or mycophenolate mofetil, final visual outcome in our study was excellent. Ocular immunology and inflammation • 2025-02-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 39190826 ↗ |
Mycophenolic Acid Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.0985/unit (~$2.96/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $34.50 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 12 Anonymous DotMD Community Micro-Logs | $12.49 / mo | View logs ↓ |
Mycophenolic Acid Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Mycophenolic Acid RxNorm Concept ID | 485020 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.0985 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $34.50 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $12.49 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (12 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Mycophenolic Acid Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Mycophenolic Acid integrating DailyMed SPL (2026-07-31), CMS NADAC ($0.0985/unit), and 12 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Mycophenolic Acid community threads and patient logs by age, biological sex, dosage, and treatment duration.